Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-04
2011-01-04
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07863422
ABSTRACT:
The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.
REFERENCES:
patent: 5364934 (1994-11-01), Drayna et al.
patent: 6569992 (2003-05-01), LaFleur et al.
patent: 7153950 (2006-12-01), Clark et al.
patent: 7479544 (2009-01-01), Clark et al.
patent: 2004/0175380 (2004-09-01), Allison et al.
patent: 2007/0161061 (2007-07-01), Clark et al.
patent: 2009/0081229 (2009-03-01), Clark et al.
patent: 2009/0175855 (2009-07-01), Clark et al.
patent: 1 033 401 (2000-09-01), None
patent: 2001-269182 (2001-10-01), None
patent: 2002-502589 (2002-01-01), None
patent: WO 99/40100 (1999-08-01), None
patent: WO 01/10482 (2001-02-01), None
patent: WO 01/75166 (2001-10-01), None
patent: 02/070706 (2002-09-01), None
patent: WO 02/072794 (2002-09-01), None
patent: 2004/039394 (2004-05-01), None
patent: 2004/101756 (2004-11-01), None
patent: 2005/113003 (2005-12-01), None
patent: 2006/054961 (2006-05-01), None
patent: 2006/063067 (2006-06-01), None
patent: 2007/001459 (2007-01-01), None
Altschul and Gish, “Local Alignment Statistics”Methods in Enzymology266:460-480 (1996).
Attwood, Teresa K., “The Babel of Bioinformatics”Science290:471-473 (2000).
Bolton, C.,, “Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment”Multiple Sclerosis. 1:143-149 (1995).
Carfi et al., “Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor HveA”Molecular Cell8:169-179 (Jul. 2001).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”Journal of Molecular Biology293(4) :865-881 (1999).
Cheung et al., “Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpresvirus entry mediator cosignaling pathway ”Proc. Natl. Acad. Sci. USA102:13218-13223 (2005).
Coligan et al., “Proliferative Assays for T Cell Function”Current Protocols in Immunology, John Wiley & Sons, Inc., Chapter 3.12, vol. 1 (1991).
Compaan et al., “Attenuating Lymphocyte Activity, The Crystal Structure of the BTLA-HVEM Complex”The Journal of Biological Chemistry280:39553-39561 (2005).
Croft, Michael, “The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA”Trends in Immunology26:292-294 (2005).
Deppong et al, “Cutting Edge: B and T Lymphocyte Attenuator are Programmed Death Receptor-1 Inhibitory Receptors are Required for Termination of Acute Allergic Airway Inflammation”Journal of Immunology176:3909-3913 (2006).
Gavrieli et al., “BTLA and HVEM Cross Talk Regulates Inhibition and Costimulation”Advances in Immunology92:157-185 (2006).
Gonzalez et al., “A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator”Proc. Natl. Acad. Sci. USA102:1116-1121 (2005).
Hakim et al., “Animal Models of Acute and Chronic Graft-Versus-Host Disease”Current Protocols in Immunology(unit 4.3, supplement 27), J E Coligan, A M Kruisbeek, D H Marglies, E M Shev, John Wiley & Sons, Inc (1998).
Hurchla et al, “B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells”Journal of Immunology174:3377-3385 (2005).
Marsters et al., “Identification of a Ligand for the Death-Domain-Containing Receptor Apo3”Current Biology8(9) :525-528 (1998).
Mauri et al., “LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator”Immunity8 (1) :21-30 (Jan. 1998).
Metzler et al., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28”Nature Structural Biol. 4(7) :527-531 (Jul. 1997).
Milne et al., “Function of Herpes Simplex Virus Type 1 gD Mutants with Different Receptor-Binding Affinities in Virus Entry and Fusion”Journal of Virology77 (16) :8962-8972 (Aug. 2003).
Montgomery et al., “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family”Cell87(3) :427-436 (1996).
Murphy et al., “Balancing co-stimulation and inhibition with BTLA and HVEM”Nature Reviews/Immunology6:671-681 (2006).
Sagawa et al., “The Protein-tyrosine Phosphatase SHP-2 Associates with Tyrosine-Phosphorylated Adhesion Molecule PECAM-1 (CD31)”Journal of Biological Chemistry272(49) :31086-31091 (Dec. 5, 1997).
Sarrias et al., “The Three HveA Receptor Ligands, gD, LT-α and LIGHT Bind to Distinct Sites on HveA”Molecular Immunology37:665-673 (2000).
Sedy et al., “B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator”Nature Immunology6:90-98 (2005).
Skolnick et al., “From Genes to protein structure and function: novel applications of computational approahces in the genomic era”TIBTECH18:34-39 (Jan. 2000).
Tao et al., “Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts”Journal of Immunology175:5774-5782 (2005).
Watanabe N., et al.,, “BTLA is a Lymphocyte Inhibitory Receptor with Similarities to CTLA-4 and PD-1”Nature Immunology4(7) :670-679 (Jul. 2003).
Williams et al., “The immunoglobulin superfamily—domains for cell surface recognition”Ann. Rev. Immunol. 6:381-405 (1988).
Costello et al, “Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity”Leukemia17:2500-2507 (2003).
Notice of Rejection (translation) mailed Nov. 13, 2008, in JP Application No. 2004-548251.
PCT International Search Report and Written Opinion of the International Searching Authority, mailed Nov. 7, 2008, for PCT International Application No. PCT/US2008/056765, filed Mar. 13, 2008.
Vendel et al., “B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK”The Journal of Immunology182:1509-1517 (2009).
Clark Hilary
Eaton Daniel L.
Gonzalez Lino
Gurney Austin L.
Loyet Kelly
Genentech Inc.
Ouspenski Ilia
Pasqualone Danielle M.
LandOfFree
Anti-PRO87299 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-PRO87299 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PRO87299 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672385